Sinil Financial Statements From 2010 to 2025
| 012790 Stock | KRW 6,550 40.00 0.61% |
Check Sinil Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sinil Pharmaceutical's main balance sheet or income statement drivers, such as , as well as many indicators such as . Sinil financial statements analysis is a perfect complement when working with Sinil Pharmaceutical Valuation or Volatility modules.
Sinil |
Sinil Pharmaceutical Co Company Current Valuation Analysis
Sinil Pharmaceutical's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Sinil Pharmaceutical Current Valuation | 159.61 B |
Most of Sinil Pharmaceutical's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sinil Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Sinil Pharmaceutical Co has a Current Valuation of 159.61 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Pharmaceuticals industry. The current valuation for all Republic of Korea stocks is significantly lower than that of the firm.
Sinil Pharmaceutical Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sinil Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Sinil Pharmaceutical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sinil Pharmaceutical competition to find correlations between indicators driving Sinil Pharmaceutical's intrinsic value. More Info.Sinil Pharmaceutical Co is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The ratio of Return On Equity to Return On Asset for Sinil Pharmaceutical Co is about 388.12 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Sinil Pharmaceutical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Sinil Pharmaceutical's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Sinil Pharmaceutical Financial Statements
Sinil Pharmaceutical stakeholders use historical fundamental indicators, such as Sinil Pharmaceutical's revenue or net income, to determine how well the company is positioned to perform in the future. Although Sinil Pharmaceutical investors may analyze each financial statement separately, they are all interrelated. For example, changes in Sinil Pharmaceutical's assets and liabilities are reflected in the revenues and expenses on Sinil Pharmaceutical's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Sinil Pharmaceutical Co. Please read more on our technical analysis and fundamental analysis pages.
Sinil Pharmaceutical Co., Ltd. manufactures, markets, and sells pharmaceutical products in South Korea. Sinil Pharmaceutical Co., Ltd. was founded in 1971 and is headquartered in Seoul, South Korea. Shinil Pharm is traded on Korean Securities Dealers Automated Quotations in South Korea.
Pair Trading with Sinil Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sinil Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sinil Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving together with Sinil Stock
The ability to find closely correlated positions to Sinil Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sinil Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sinil Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sinil Pharmaceutical Co to buy it.
The correlation of Sinil Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sinil Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sinil Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sinil Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Sinil Stock
Sinil Pharmaceutical financial ratios help investors to determine whether Sinil Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sinil with respect to the benefits of owning Sinil Pharmaceutical security.